Effect of interferon alpha2b plus ribavirin treatment on selected growth factors in respect to inflammation and fibrosis in chronic hepatitis C

World Journal of Gastroenterology

Volumn 11, Issue 12, 2005, Pages 1854-1858

  Anatol, Panasiuk ^a   Robert, Flisiak ^a   Danuta, Prokopowicz ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Chronic hepatitis C; Growth factor; Interferon alfa 2b; Liver biopsy; Ribivirin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; BILIRUBIN; EPIDERMAL GROWTH FACTOR; HEPATITIS C ANTIBODY; PLATELET DERIVED GROWTH FACTOR; PROTHROMBIN; REBETRON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; SCATTER FACTOR; THROMBOPOIETIN; VIRUS RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE COUNT; FEMALE; HEPATITIS C; HISTOPATHOLOGY; HORMONE BLOOD LEVEL; HUMAN; HUMAN TISSUE; LEUKOCYTE COUNT; LIVER BIOPSY; LIVER FAILURE; LIVER FIBROSIS; MALE; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTE COUNT; VIRUS REPLICATION;

EID: 17144432260     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i12.1854     Document Type: Article

References (30)

1. Poynard T, Imbert-Bismut F, Ratziu V, Chevret S, Jardel C, Moussalli J, Messous D, Degos F. GERMED cyt04 group. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: Longitudinal validation in a randomized trial. J Viral Hepat 2002; 9: 128-133
2. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001; 34: 730-739
3. Shimotohno K. Hepatitis C virus and its pathogenesis. Semin Cancer Biol 2000; 10: 233-240
4. Kalkeri G, Khalap N, Garry RF, Fermin CD, Dash S. Hepatitis C virus protein expression induces apoptosis in HepG2 cells. Virology 2001; 282: 26-37
5. Zeuzem S. The kinetics of hepatitis C virus infection. Clin Liver Dis 2001; 5: 917-930
6. Castet V, Fournier C, Soulier A, Brillet R, Coste J, Larrey D, Dhumeaux D, Maurel P, Pawlotsky JM. Alpha interferon inhibits hepatitis C virus replication in primary human hepatocytes infected in vitro. J Virol 2002; 76: 8189-8199
7. Lau JY, Tam RC, Liang TJ, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002; 35: 1002-1009
8. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling MH, Albrecht J. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-1313
9. Fukujin H, Fujita T, Mine T. Additivity of the proliferative effects of HGF/S.F. and EGF on hepatocytes. Biochem Biophys Res Commun 2000; 278: 698-703
10. Scheving LA, Stevenson MC, Taylormoore JM, Traxler P, Russell WE. Integral role of the EGF receptor in HGF-mediated hepatocyte proliferation. Biochem Biophys Res Commun 2002; 290: 197-203
11. Yamashita K, Matsuoka H, Ochiai T, Matsushita R, Kubuki Y, Suzuki M, Tsubouchi H. Hepatocyte growth factor/scatter factor enhances the thrombopoietin mRNA expression in rat hepatocytes and cirrhotic rat livers. J Gastroenterol Hepatol 2000; 15: 83-90
12. Lou SM, Li YM, Wang KM, Cai WM, Weng HL. Expression of platelet-derived growth factor-BB in liver tissues of patients with chronic hepatitis B. World J Gastroenterol 2004; 10: 385-388
13. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372-374
14. Saracco G, Olivero A, Ciancio A, Carenzi S, Smedile A, Cariti G, Andreoni M, Orsi PG, Biglino A, Tabone M, Roffi L, Croce G, Manca A, Tappero G, Ciccone G, Rizzetto M. A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy. Hepatology 2002; 36(4 Pt 1): 959-966
15. Mannaioni PF, Di Bello MG, Masini E. Platelets and inflammation: Role of platelet-derived growth factor, adhesion molecules and histamine. Inflamm Res 1997; 46: 4-18
16. Pinzani M, Milani S, Herbst H, DeFranco R, Grappone C, Gentilini A, Caligiuri A, Pellegrini G, Ngo DV, Romanelli RG, Gentilini P. Expression of platelet-derived growth factor and its receptors in normal human liver and during active hepatic fibrosis. Am J Pathol 1996; 148: 785-800
17. Carloni V, Defranco RM, Caligiuri A, Gentilini A, Sciammetta SC, Baldi E, Lottini B, Gentilini P, Pinzani M. Cell adhesion regulates platelet-derived growth factor-induced MAP kinase and PI-3 kinase activation in stellate cells. Hepatology 2002; 36: 582-591
18. 1 as an indicator of hepatic function impairment in liver cirrhosis. Cytokine 2000; 12: 677-681
19. Tsushima H, Kawata S, Tamura S, Ito N, Shirai Y, Kiso S, Yamada A, Oshikawa O, Matsuzawa Y. Reduced plasma transforming growth factor-beta1 levels in patients with chronic hepatitis C after interferon-alpha therapy: Association with regression of hepatic fibrosis. J Hepatol 1999; 30: 1-7
20. Adinolfi LE, Giordano MG, Andreana A, Tripodi MF, Utili R, Cesaro G, Ragone E, Durante Mangoni E, Ruggiero G. Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. Br J Haematol 2001; 113: 590-595
21. Tacke F, Trautwein C, Zhao S, Andreeff M, Manns MP, Ganser A, Schoffski P. Quantification of hepatic thrombopoietin mRNA transcripts in patients with chronic liver diseases shows maintained gene expression in different etiologies of liver cirrhosis. Liver 2002; 22: 205-212
22. Matsumoto K, Nakamura T. Hepatocyte growth factor: molecular structure, roles in liver regeneration, and other biological functions. Crit Rev Oncog 1992; 3: 27-54
23. Nayeri F, Nilsson I, Brudin L, Fryden A, Soderstrom C, Forsberg P. High serum hepatocyte growth factor levels in the acute stage of community-acquired infectious diseases. Scand J Infect Dis 2002; 34: 127-130
24. Bilezikci B, Haberal AN, Demirhan B. Hepatocyte growth factor in patients with three different stages of chronic liver disease including hepatocellular carcinoma, cirrhosis and chronic hepatitis: An immunohistochemical study. Can J Gastroenterol 2001; 15: 159-165
25. Shiota G, Umeki K, Okano J, Kawasaki H. Hepatocyte growth factor and acute phase proteins in patients with chronic liver diseases. J Med 1995; 26: 295-308
26. Shiota G, Okano J, Kawasaki H, Kawamoto T, Nakamura T. Serum hepatocyte growth factor levels in liver diseases: Clinical implications. Hepatology 1995; 21: 106-112
27. Yamagami H, Moriyama M, Tanaka N, Arakawa Y. Detection of serum and intrahepatic human hepatocyte growth factor in patients with type C liver diseases. Intervirology 2001; 44: 36-42
28. Miyazaki M, Akiyama I, Sakaguchi M, Nakashima E, Okada M, Kataoka K, Huh NH. Improved conditions to induce hepatocytes from rat bone marrow cells in culture. Biochem Biophys Res Commun 2002; 298: 24-29
29. Caballero ME, Berlanga J, Ramirez D, Lopez-Saura P, Gozalez R, Floyd DN, Marchbank T, Playford RJ. Epidermal growth factor reduces multiorgan failure induced by thioacetamide. Gut 2001; 48: 34-40
30. Komuves LG, Feren A, Jones AL, Fodor E. Expression of epidermal growth factor and its receptor in cirrhotic liver disease. J Histochem Cytochem 2000; 48: 821-830